Virologic efficacy of boosted double versus boosted single protease inhibitor therapy

AIDS

Volumn 21, Issue 12, 2007, Pages 1547-1554

  Petersen, Maya L ^a   Wang, Yue ^a   Van Der Laan, Mark J ^a   Rhee, Soo Yon ^b   Shafer, Robert W ^b   Fessel, W Jeffrey ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Clinical Trials Unit   (United States)

Author keywords

Boosted protease inhibitors; Drug resistance; Marginal structural models; Salvage therapy; Virologic suppression

Indexed keywords

AMPRENAVIR; ATAZANAVIR; INDINAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ANAMNESIS; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RNA ANALYSIS; SALVAGE THERAPY; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG EVALUATION; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; RETROSPECTIVE STUDIES; RNA, VIRAL; SALVAGE THERAPY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34447545491     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32825a69a8     Document Type: Article

References (14)

1. Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba AD. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr 2004; 36:921-928.
2. la Porte CJ, Wasmuth JC, Schneider K, Rockstroh JK, Burger DM. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 2003; 17:1700-1702.
3. Smith GH, Boulassel MR, Klien M, Gilmore N, MacLeod J, LeBlanc R, et al. Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. HIV Clin Trials 2005; 6:63-72.
4. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570.
5. Robins JM. Marginal structural models versus structural nested models as tools for causal inference. In: Statistical models in epidemiology, the environment, and clinical trials. Edited by Halloran ME, Berry D. New York: Springer-Verlag; 1999. pp. 95-134.
6. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560.
7. Hammer S, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Recommendations of the International AIDS Society-USA Panel. JAMA 2006; 296:827-843.
8. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://aidsinfo.nih.gov/guidelines.
9. Neugebauer R, van der Laan M. Why prefer double robust estimates? Illustration with causal point treatment studies. J Stat Plan Inference 2005; 129:405-426.
10. Robins JM. Robust estimation in sequentially ignorable missing data and causal inference models. Proceedings of the Bayesian Statistical Section, American Statistical Association Alexandria, Virginia: American Statistical Association; 2000. pp. 6-10.
11. van der Laan MJ, Robins JM. In: Unified Methods for Censored Longitudinal Data and Causality. New York: Springer-Verlag; 2002. pp. 329-347.
12. Sinisi S, van der Laan M. Deletion/substitution/addition algorithm in learning with applications in genomics. Stat Appl Genet Mol Biol 2004; 3:18.
13. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, et al. Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288:169-180.
14. Loutfy M, Raboud J, Thompson C, Tseng A, Abdurrahman Z, Kovacs C, et al. Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy. HIV Clin Trials 2003; 4:301-310.